Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Has results × tepotinib × Clear all
NCT03492437 2023-08-07

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
20 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01014936 2022-08-24

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

EMD Serono

Phase 1 Completed
149 enrolled 41 charts
Other solid neoplasm

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Data powered by HemOnc (CC BY 4.0) Colophon âš¡